Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Treatment-Refractory Narcolepsy Type 1
NCT07871006Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in narcolepsy type 1 (NT1), sponsored by Xijing Hospital. Started Oct 2025; status: recruiting.
02
Drugs
ofatumumab
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT07871006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871006.